Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Seagate Technology Holdings PLC — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.18 (market cap $6.04B), while Seagate Technology Holdings PLC trades at $772.99 (market cap $176.19B). The key difference: Seagate Technology Holdings PLC is far larger — about 29.2× Iovance Biotherapeutics Inc. Common Stock's market cap, and Seagate Technology Holdings PLC pays a 0.38% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Seagate Technology Holdings PLC for 41 Days on average.
| IOVA | STX | |
|---|---|---|
Market Cap | $6.04B | $176.19B |
Volume | 14,805,993 | 5,061,875 |
Sector | Health | Technology |
52-Week High | $14.82 | $1.09K |
52-Week Low | $1.81 | $211.63 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $5.97B | $178.34B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Seagate Technology (STX) trades at $807.34, up 0.21% with recent volatility driven by AI storage competition concerns. The stock shows strong profitability with 26.11% net margin and 371.53% ROE, though valuation ratios appear elevated (P/E 55.74, P/B 81.31). Recent earnings consistently beat expectations, with Q2 2026 EPS of $5.71 surpassing the $5.10 estimate. Technical indicators show bearish momentum with support at $794 and resistance at $816.
Outlook remains cautiously optimistic given strong AI-driven storage demand and analyst consensus price target of $1,130. Key risks include increased competition from Toshiba's planned production expansion and potential margin compression. The company's negative shareholder equity and high debt levels warrant monitoring, though projected 2026 revenue growth to $12.2B with $3.2B net income suggests continued operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
